Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in pediatric intensive care units in France, September 2023 -January 2024
Résumé
In September 2023, France was one of the first countries that started a national immunization campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of pediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case-control study based on the test-negative-design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5-88.7) in the main analysis, and 80.6% (61.6-90.3) and 80.4% (61.7-89.9) in two sensitivity analyses. These real-world estimates confirmed the efficacy observed in clinical studies.
Fichier principal
Nirsevimab_effectiveness_Santé publique France_2024.03.12.pdf (576.24 Ko)
Télécharger le fichier
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|---|
| Licence |
